Abstract
Treatment of MIN mice with the nonsteroidal anti-inflammatory drug, nabumetone, resulted in a dose-dependent suppression of intestinal tumorigenesis. In both the uninvolved MIN mouse colonic epithelium and HT-29 colon cancer cells, nabumetone downregulated the anti-apoptotic protein, Bcl-2, with concomitant induction of apoptosis, suggesting a potential mechanism for colon cancer chemoprevention. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baretton GB, Diebold J, Cristoforis G, Vogt M, Muller C, Doffer K, Schneiderbanger K, Schmidt M and Lohrs U (1996) Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas: Aspects in carcinogenesis and prognostic significance. Cancer 77: 255–264
Barnes CJ, Hardman EE and Lee M (1998) Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastro 114: 873–877
Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B and Kinzer KW (1996) Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 17: 1757–1760
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvein TK, Schnitzer TJ and Weaver A (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528
Boolbol SK, Danneberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCrosse JJ and Bertagnolli MM (1996) Cycloxygenase-2 over-expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56: 2556–2560
Carr NJ (2000) M30 Expression demonstrates apoptotic cells, correlates with in situ end-labeling and is associated with Ki-67 expression in large intestinal neoplasms. Arch Pathol Lab Med 124: 1768–1772
Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O and Langenbach R (2000) Genetic Disruption of ptgs-1, as well as ptgs-2 Reduces Intestional Tumorigenesis in the Min mice. Cancer Res 60: 4705–4708
Chung DC (2000) The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterol 119: 854–865
Hague A, Bracey TS, Hicks DJ, Reed JC and Paraskeva C (1998) Decreased levels of p26-Bcl-2, but not p30 phosphorylated Bcl-2, precede TGFβ1-induced apoptosis in colorectal adenoma cells. Carcinogenesis 19: 1691–1695
Huang JQ, Sridhar S and Hunt RH (1999) Gastrointestinal safety profile of nabumetone: a meta-analysis. Am J Med 107: 55S–61S
Jacoby RG, Seifert K, Cole CE, Kelloff G and Lubet RA (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse models of adenomatous polyposis. Cancer Res 260: 5040–5044
Janne PA and Mayer RJ (2000) Chemoprevention of colorectal cancer. N Engl J Med 342: 1960–1968
Liu LU, Holt PR, Krivosheyev V and Moss SF (1999) Human right and left colon differ in epithelial apoptosis and in expression of Bak, a pro-apoptotic Bcl-2 homologue. Gut 45: 45–50
McAdams BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA and FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272–277
McEntee MF, Chiu CH and Whelan J (1999) Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 20: 635–640
Roy HK, Bissonnette M, Frawley BP Jr, Wali RK, Niedziela SM, Earnest D and Brasitus TA (1995) Selective preservation of protein kinase C-zeta in the chemoprevention of azoxymethane-inducedcolonic tumors by piroxicam. FEBS Lett 366: 143–145
Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2in human colon cancer cells. Cancer Res 58: 362–366
Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P and Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. Nature Medicine 6: 1024–1028
Tsujimoto Y and Shimizu S (2000) Bcl-2 family: life-or-death switch. FEBS Lett 466: 6–10
Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA and Vane JR (1999) Nonsteroid drug selectivities for cyclo-oxygenase—1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96: 7563–7568
Williams CS, Smalley W and DuBois RN (1997) Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 100: 1325–1329
Winde G, Schmid KW, Brandt B, Muller O and Osswald H (1997) Clinical and Genomic Influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 40: 1156–1168
Zhang L, Yu J Park BH, Kinzler KW and Vogelstein B (2000) Role of BAX in the apoptotic response to anticancer agents. Science 290: 989–992
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Roy, H., Karoski, W., Ratashak, A. et al. Chemoprevention of intestinal tumorigenesis by nabumetone: induction of apoptosis and Bcl-2 downregulation. Br J Cancer 84, 1412–1416 (2001). https://doi.org/10.1054/bjoc.2001.1807
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1807